Osteoarthritis Therapeutics Market Report 2026

The osteoarthritis therapeutics market size has grown strongly in recent years. It will grow from $8.87 billion in 2025 to $9.63 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rising prevalence of osteoarthritis, aging global population, widespread use of NSAIDs and analgesics, expansion of orthopedic care services, availability of established pain management therapies.

The osteoarthritis therapeutics market size is expected to see strong growth in the next few years. It will grow to $13.21 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing development of dmoads, rising demand for minimally invasive therapies, expansion of biologic and cell-based treatments, growing focus on personalized osteoarthritis care, increased investment in joint disease research. Major trends in the forecast period include increasing adoption of disease-modifying osteoarthritis therapies, rising use of regenerative medicine approaches, growing focus on non-opioid pain management, expansion of injectable and intra-articular treatments, enhanced emphasis on early disease intervention.

The rising incidence of sports injuries is anticipated to drive the growth of the osteoarthritis therapeutics market. A sports injury is any harm or damage that occurs during athletic or sports activities. These injuries can vary in severity, ranging from minor to severe, and may affect different parts of the body. The increase in sports injuries is primarily attributed to higher participation in sports and the growing intensity and competitiveness of these activities. Osteoarthritis therapeutics are utilized in sports injuries to alleviate pain and inflammation and to enhance joint function in athletes experiencing joint degeneration. For example, in July 2025, according to the Australian Institute of Health and Welfare, an Australia-based government agency, approximately 62,100 sports injuries in Australia during 2023-24 resulted in hospital admissions. Of these, males represented 70% of all hospitalizations (around 43,800 cases), while females accounted for nearly 30% (about 18,300 cases). Consequently, the increasing number of sports injuries is contributing to the expansion of the osteoarthritis therapeutics market.

Major companies operating in the osteoarthritis therapeutics market are concentrating on developing innovative solutions, such as new approaches for tissue regeneration in osteoarthritis. Tissue regeneration in osteoarthritis involves repairing or replacing damaged cartilage and joint tissues to restore normal function and reduce pain. For example, in May 2023, the Advanced Research Projects Agency for Health (ARPA-H), a US-based government agency, launched the Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program. The NITRO program, initiated by ARPA-H, focuses on creating advanced injectable therapies that promote cartilage repair by utilizing biological pathways similar to those active during embryonic development. Key aspects include a collaborative multimodal approach among research teams and sophisticated testing methods, such as "joint-on-a-chip" platforms that replicate joint environments, aiming to develop regenerative solutions targeting the root causes of osteoarthritis.

In February 2025, Pacira BioSciences, a US-based biotechnology company, acquired GQ Bio Therapeutics for approximately US$32 million. Through this acquisition, Pacira seeks to enhance its osteoarthritis therapy pipeline by incorporating GQ Bio’s high-capacity adenovirus (HCAd) gene therapy platform and advancing the development of PCRX-201 (enekinragene inzadenovec) for knee osteoarthritis. GQ Bio Therapeutics, based in Germany, develops gene therapy vectors and gene therapies specifically targeting osteoarthritis.

Major companies operating in the osteoarthritis therapeutics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Taisho Pharmaceutical Co. Ltd., Ferring Pharmaceuticals, Bioventus LLC, Flexion Therapeutics Inc., Anika Therapeutics Inc., Seikagaku Corporation, Galapagos NV, Regeneron Pharmaceuticals Inc., Samumed LLC, Kolon Life Science Inc., Horizon Therapeutics plc.

North America was the largest region in the osteoarthritis therapeutics market in 2025. The regions covered in the osteoarthritis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the osteoarthritis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the osteoarthritis therapeutics market by increasing costs of imported active pharmaceutical ingredients, biologics, syringes, injectable devices, and specialized drug delivery systems. Pharmaceutical manufacturers and healthcare providers in North America and Europe are most affected due to reliance on global supply chains, while Asia-Pacific faces higher production input costs. These tariffs are increasing drug pricing pressures and affecting treatment affordability. However, they are also encouraging regional drug manufacturing, local api production, and diversification of supply chains that support long-term market stability.

The osteoarthritis therapeutics market research report is one of a series of new reports that provides osteoarthritis therapeutics market statistics, including osteoarthritis therapeutics industry global market size, regional shares, competitors with a osteoarthritis therapeutics market share, detailed osteoarthritis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the osteoarthritis therapeutics industry. This osteoarthritis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Osteoarthritis therapeutics encompass the medical treatments and interventions used to manage and relieve the symptoms of osteoarthritis, a degenerative joint disorder marked by the deterioration of cartilage and the underlying bone. These therapeutics consist of medications, physical therapies, lifestyle adjustments, and, in certain cases, surgical procedures. The main objectives of osteoarthritis therapeutics are to alleviate pain, enhance joint function, and improve the quality of life for individuals affected by the condition.

The primary drug categories in osteoarthritis therapeutics include viscosupplementation agents, nonsteroidal anti-inflammatory drugs, analgesics, corticosteroids, and others. Viscosupplementation agents are administered directly into the joint to provide lubrication and cushioning, helping reduce pain and improve mobility. Osteoarthritis can affect various anatomical sites, including the knee, hip, hand, and others, and treatments can be delivered through parenteral, topical, or oral routes. The different sales channels comprise prescription drugs and over-the-counter drugs, which are utilized by various end-users such as hospital pharmacies, retail pharmacies, and others.

The osteoarthritis therapeutics market consists of revenues earned by entities by providing services such as exercises and therapies, diagnostic services, and pain management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteoarthritis therapeutics market also includes sales of pain relievers, corticosteroids, hyaluronic acid injections, and assistive devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.